Skip to main
PSNL

Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc (PSNL) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 0%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Personalis Inc. has reported a significant increase of 41% quarter-over-quarter in its NeXT Personal Dx volumes for Q4 2025, which exceeds prior expectations and points to a robust demand trajectory. The company's partnership with Tempus is anticipated to further accelerate marketing efforts for its tests, potentially driving additional volume growth in the upcoming quarters. Furthermore, the recent acquisition of Medicare coverage and pricing for the NeXT Personal MRD test is expected to enhance its market presence, as strong performance in detecting minimal residual disease demonstrates the product's value in early cancer recurrence detection.

Bears say

Personalis Inc. has faced a negative outlook primarily due to a downgrade in its revenue guidance for Q4 2025, attributed to a general slowdown in the biopharma sector and logistical issues with global sample handling. The company's reliance on its genetic sequencing and analytics solutions has led to significant losses, accompanied by debt on its balance sheet, raising concerns about its ability to achieve future profitability. Additionally, the decline in revenue from pharma services, particularly linked to reduced activity in Moderna's Phase III melanoma trial, further reinforces the challenges the company is facing in sustaining its operations and growth.

Personalis Inc (PSNL) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 0% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Personalis Inc (PSNL) Forecast

Analysts have given Personalis Inc (PSNL) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Personalis Inc (PSNL) has a Strong Buy consensus rating as of Apr 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Personalis Inc (PSNL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.